180 Life Sciences Files 8-K

TL;DR

180 Life Sciences filed an 8-K on Oct 4th, watch for new financials.

AI Summary

180 Life Sciences Corp. filed an 8-K on October 9, 2024, reporting an event that occurred on October 4, 2024. The filing is related to financial statements and exhibits, and other events. The company was formerly known as KBL Merger Corp. IV and changed its name on November 15, 2016.

Why It Matters

This 8-K filing indicates that 180 Life Sciences Corp. has submitted important financial statements and exhibits, which could provide insights into the company's current financial health and operational status.

Risk Assessment

Risk Level: low — This filing is a routine 8-K for financial statements and exhibits, not indicating any immediate significant operational or financial distress.

Key Players & Entities

• 180 Life Sciences Corp. (company) — Registrant
• KBL Merger Corp. IV (company) — Former company name
• October 4, 2024 (date) — Earliest event date
• October 9, 2024 (date) — Filing date

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share ATNF The NASDAQ Stock Ma

Filing Documents

• ea0217109-8k_180life.htm (8-K) — 38KB
• ea021710901ex99-1_180life.htm (EX-99.1) — 19KB
• 0001213900-24-086401.txt ( ) — 283KB
• atnf-20241004.xsd (EX-101.SCH) — 4KB
• atnf-20241004_def.xml (EX-101.DEF) — 26KB
• atnf-20241004_lab.xml (EX-101.LAB) — 36KB
• atnf-20241004_pre.xml (EX-101.PRE) — 25KB
• ea0217109-8k_180life_htm.xml (XML) — 6KB

01 Other Events

Item 8.01 Other Events On October 4, 2024, 180 Life Sciences Corp. (the " Company ") received a letter from Nasdaq confirming that the Company has regained compliance with the minimum shareholder equity requirement in Listing Rule 5550(b)(1) (the " Equity Rule "), as required by the Nasdaq Hearing Panel's (" Panel ") decision dated July 1, 2024, as amended. Nasdaq also advised the Company that in application of Listing Rule 5815(d)(4)(B), the Company will be subject to a mandatory panel monitor for a period of one year from the date of such letter. If, within that one-year monitoring period, the Nasdaq Listing Qualifications staff (" Staff ") finds that the Company is no longer in compliance with the Equity Rule, then, notwithstanding Rule 5810(c)(2), the Company will not be permitted to provide Staff with a plan of compliance with respect to such deficiency and the Staff will not be permitted to grant additional time for the Company to regain compliance with respect to such deficiency, nor will the Company be afforded an applicable cure or compliance period pursuant to Rule 5810(c)(3). Instead, the Staff will issue a Delist Determination Letter and the Company will have an opportunity to request a new hearing with the initial Panel or a newly convened Hearings Panel if the initial Panel is unavailable. The Company will have the opportunity to respond/present to the Hearings Panel as provided by Listing Rule 5815(d)(4)(C) and the Company's securities may at that time be delisted from Nasdaq. Notwithstanding the above, the Company remains out of compliance with the audit committee requirements for continued listing on Nasdaq set forth in Listing Rule 5605(c)(2), which requires that listed companies maintain an audit committee of at least three independent directors. Nasdaq provided the Company a cure period in order to regain compliance as follows: until the earlier of the Company's next annual shareholders' meeting or May 7, 2025; or if the next annual sharehold

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release issued dated October 9, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) Forward- Looking Statements This Current Report on Form 8-K contains forward-looking statements that are made pursuant to the safe harbor provisions within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended and the Private Securities Litigation Reform Act, as amended. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties, many of which are beyond our control, that may cause actual results or events to differ materially from those projected. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled " Risk Factors " and elsewhere in our Annual Reports on Form 10-K and in our other filings with the SEC, including, without limitation, our reports on Forms 8-K and 10-Q, all of which can be obtained on the SEC website at www.sec.gov . Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 9, 2024 180 LIFE SCIENCES CORP. By: /s/ Blair Jordan Name: Blair Jordan Title: Interim Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR